Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005 - PubMed (original) (raw)

Review

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005

J J Holst. Diabetologia. 2006 Feb.

Abstract

The incretin hormones are intestinal polypeptides that enhance postprandial insulin secretion. Gastric inhibitory polypeptide (GIP) was initially thought to regulate gastric acid secretion, whereas glucagon-like peptide-1 (GLP-1) was discovered as a result of a systematic search for intestinal insulinotropic products of proglucagon gene expression. The incretin effect is markedly impaired or absent in patients with type 2 diabetes because of decreased secretion of GLP-1 and a loss of the insulinotropic effects of GIP. Metabolic control can be restored or greatly improved by administration of exogenous GLP-1, but this peptide is almost immediately degraded by dipeptidyl peptidase IV (DPP-IV), and therefore has little clinical value. DPP-IV-resistant analogues (incretin mimetics) have been identified or developed, and inhibitors of DPP-IV have also proved effective in protecting endogenous GLP-1 (and GIP) from degradation. Both principles have been tested in clinical studies. The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA(1)c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years. The DPP-IV inhibitors, given once or twice daily by mouth, also appear to provide lasting improvement in HbA(1)c, but are weight-neutral. The first incretin mimetic has reached the market in the US, and applications for approval of the first inhibitors are expected to be filed early in 2006.

PubMed Disclaimer

Similar articles

• Incretins: their physiology and application in the treatment of diabetes mellitus.
  Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S. Tasyurek HM, et al. Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Diabetes Metab Res Rev. 2014. PMID: 24989141 Review.
• Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
  Verspohl EJ. Verspohl EJ. Pharmacol Ther. 2009 Oct;124(1):113-38. doi: 10.1016/j.pharmthera.2009.06.002. Epub 2009 Jun 21. Pharmacol Ther. 2009. PMID: 19545590 Review.
• Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
  Neumiller JJ. Neumiller JJ. J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. J Am Pharm Assoc (2003). 2009. PMID: 19801361 Review.
• Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
  Holst JJ. Holst JJ. Expert Opin Emerg Drugs. 2004 May;9(1):155-66. doi: 10.1517/eoed.9.1.155.32952. Expert Opin Emerg Drugs. 2004. PMID: 15155141 Review.
• Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
  Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ. Maida A, et al. Gastroenterology. 2009 Dec;137(6):2146-57. doi: 10.1053/j.gastro.2009.09.004. Epub 2009 Sep 17. Gastroenterology. 2009. PMID: 19766644

Cited by

• The Impact of Bariatric Surgery on Weight Loss and Glycemic Control in Patients With Obesity and Type 2 Diabetes: A Systematic Review.
  Mirghani H, Alamrani SAS, Alkonani AA, Al Madshush AM. Mirghani H, et al. Cureus. 2023 Nov 20;15(11):e49122. doi: 10.7759/cureus.49122. eCollection 2023 Nov. Cureus. 2023. PMID: 38125226 Free PMC article. Review.
• Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes.
  Pelluri R, Kongara S, Nagasubramanian VR, Mahadevan S, Chimakurthy J. Pelluri R, et al. J Endocrinol Invest. 2023 May;46(5):855-867. doi: 10.1007/s40618-023-02003-9. Epub 2023 Jan 9. J Endocrinol Invest. 2023. PMID: 36624224 Review.
• Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
  Gallwitz B. Gallwitz B. Front Endocrinol (Lausanne). 2022 Oct 13;13:1004044. doi: 10.3389/fendo.2022.1004044. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36313764 Free PMC article. Review.
• cd26 Knockdown Negatively Affects Porcine Parthenogenetic Preimplantation Embryo Development.
  Hwang IS, Shim J, Oh KB, Lee H, Park MR. Hwang IS, et al. Animals (Basel). 2022 Jun 28;12(13):1662. doi: 10.3390/ani12131662. Animals (Basel). 2022. PMID: 35804561 Free PMC article.
• Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance.
  Sharma A, Virmani T, Sharma A, Chhabra V, Kumar G, Pathak K, Alhalmi A. Sharma A, et al. Diabetes Metab Syndr Obes. 2022 Jun 16;15:1845-1864. doi: 10.2147/DMSO.S369712. eCollection 2022. Diabetes Metab Syndr Obes. 2022. PMID: 35733643 Free PMC article. Review.

References

1. 1. Diabetes. 2000 May;49(5):741-8 - PubMed
2. 1. Nature. 1983 Apr 21;302(5910):716-8 - PubMed
3. 1. Endocrinology. 1995 Aug;136(8):3585-96 - PubMed
4. 1. J Biol Chem. 1991 Feb 15;266(5):2897-902 - PubMed
5. 1. Am J Physiol. 1997 Nov;273(5 Pt 1):E981-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal